Alexander Coltoff, MD nag-retweet
🚨 Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias.
I am very pleased with this collaborative effort. Grateful to @MrinalPatnaik for his mentorship.
Paper highlights 👇🏽
🧬 PPM1D mutations in clonal hematopoiesis – what really happens after chemo?
Multi center study of 337 CH/CCUS patients dissects how #PPM1D and #TP53 mutations shape therapy-related clonal hematopoiesis. 👇
1️⃣ PPM1D is the signature of therapy-related CH
•50% had PPM1D-mut/TP53-WT
•7% had PPM1D-mut/TP53-mut
•These genotypes were highly enriched in therapy-related CH/CCUS (up to 80% of cases).
2️⃣ All PPM1D mutations were truncating exon-6 variants
Median VAF only 6% — small clones, but biologically meaningful.
3️⃣ Latency after genotoxic therapy was strikingly short
Median time from last chemo/radiation to detection:
•PPM1D-mut groups: ~6 months
•TP53-mut only: ~11 months
•WT/WT: ~24 months
→ PPM1D clones emerge fast after DNA-damaging therapy.
4️⃣ Strong link with PARP inhibitors & radioligand therapy
In therapy-related CH/CCUS:
•PARPi exposure: 24–26% in PPM1D-mut vs 0–3% in WT groups
•Radioligand therapy: ~25–26% in PPM1D-mut vs near-zero otherwise.
5️⃣ Despite this… PPM1D clones rarely progressed
Rates of transformation to MDS/CMML:
•PPM1D-mut/TP53-WT: 2%
•PPM1D-mut/TP53-mut: 4%
•TP53-mut only: 18%
•WT/WT: 12%
AML transformation occurred only in WT/WT group.
6️⃣ When both PPM1D & TP53 are present, neither always “wins”
Among co-mutated patients:
•~⅓ #PPM1D-dominant
•~⅓ #TP53-dominant
•~⅓ co-dominant
Therapy-related CH showed more co-dominant competing clones, suggesting chemo creates a “Darwinian battlefield”.
7️⃣ The size of the PPM1D clone matters
Using ROC-derived cut-off:
•PPM1D VAF ≥13% → independently predicts worse PFS & OS
(HR ~2.3 for both).
Multiple PPM1D mutations ≠ worse outcome — it’s the clone size, not count.
8️⃣ Clinical message
#PPM1D mutations are:
•Common after chemo/PARPi/radioligand therapy
•Often small, fast-emerging clones
•Surprisingly low risk for malignant transformation, even with TP53 —
unless the VAF climbs ≥13%.
Take-home:
PPM1D-mut CH appears to be a therapy-selected, early-emerging, usually indolent precursor state — but rising clone size may signal real danger.
doi.org/10.1182/blooda…
English
